Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
Solace Therapeutics, Inc., today announced that data from a multicenter 221 patient randomized controlled trial has met study endpoints with statistical significance. Dr. Eric Rovner will be presenting a poster of the results from the SUCCESS Clinical Trial at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) meeting in Scottsdale, Arizona on Thursday, March, 2nd. This is the Company’s third randomized controlled trial to evaluate the safety and efficacy of the Vesair Bladder Control System; a novel, office-based, reversible treatment designed to reduce or eliminate urine leakage in female patients with Stress Urinary Incontinence (SUI). Read more.
Source: Business Wire, March 1, 2017
Source: Nursing Times, March 1, 2017
Physical activity improves health and may delay the onset of chronic diseases. For women in particular, the rate of some chronic diseases accelerates at middle age around the time of menopause; therefore it is important to identify the determinants of health-enhancing physical activity during midlife in this population. The main aim of this study was to characterize the level of physical activity and to examine the association between different female reproductive factors and objectively-measured physical activity in middle-aged women. The reproductive factors included cumulative reproductive history index, and perceived menopausal and pelvic floor dysfunction symptoms. Read more.
Source: MedicalResearch.com, Feburary 28, 2017
Hatch Medical, L.L.C., a medical device incubator and technology brokerage firm, announced today that it has entered into an agreement with MUCOM, L.L.C. to broker the sale or license of its patented male urinary incontinence device MUI Comfort™. MUI Comfort™ is an integrated external collection system that meets the needs of a growing demographic that is coping with the consequences of stress, urge, and overflow incontinence. This innovative technology is differentiated from competing products by providing a complete solution that addresses both functional and psychological aspects associated with male urinary incontinence. Read more.
Source: Yahoo Finance! February 16, 2017
Tissue regeneration gets the attention of Eun Ji Chung, a USC researcher who also studies a common and distressing problem: bladder control. Chung, an assistant professor at the USC Viterbi School of Engineering, examines how tissue regeneration could help patients with urinary incontinence caused by the loss or weakened control of the muscle controlling the release of urine from the bladder. The problem affects millions, especially women and females who have given birth. She hopes to provide a solution by restoring urethral tissue form and function. The goal: to develop biocompatible and bioactive hydrogels that can release growth factors and stimulate muscle repair using adipocytes, or fat stem cells, for the urethra, she said. Read more.
Source: USC News, February 13, 2017
Urinary stress incontinence (USI) affects 25 per cent of women over 40 with the incidence increasing with age. It’s defined as a loss of urine often with cough, sneeze, laughing, running or lifting. Yet despite the prevalence of this condition, many women do not seek help until symptoms become severe and have been ongoing for at least two years. Factors contributing to USI are childbirth, pregnancy, menopause, low back pain, weight gain and smoking. USI responds well to conservative non-surgical treatment with the first line of treatment often being pelvic floor strengthening exercises under the supervision of a physiotherapist. Physiotherapists often use biofeedback and electrical stimulation to help reeducate these muscles. Read more.
Source: The Chronicle Herald, February 8, 2017
You are invited to participate in a paid market research study about your personal experience with underactive bladder (UAB), which may also be known as impaired bladder emptying, hypotonic/flaccid bladder, detrusor underactivity/failure, voiding dysfunction, or chronic/acute urinary retention. The market research firm conducting the study would like to understand more about your personal journey and discuss potential new diagnostic and treatment options. In order to participate, you must have been diagnosed with UAB. The study consists of a 45-minute phone interview that will require internet access, and you will be compensated $100 for your time. If you are interested in participating, please click this link to see if you qualify: https://hub.m3globalresearch.com/page/r13650tdip.cfm This study is being managed by ZS, an Independent Research Firm, in compliance with marketing research standards. The study concludes on February 8, 2017.